To:

Head of Paediatric Medicines
European Medicines Agency

Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision

Actives substances(s): Etrolizumab

Invented name: Not Applicable

Latest Decision number(s): 1) P/0168/2020

Corresponding PIP number(s): 1) EMEA-001434-PIP01-13-M03

Date of initial marketing authorisation granted: Not granted

Date of authorisation of new indication, pharmaceutical form or route of administration: Not granted

Please note that development of the medicinal product above in the following **condition(s)/indication(s)**:

Ulcerative Colitis

Cronh's Disease

☒ has been discontinued

☐ has been suspended/put on long-term hold (with possible re-start at a later time)

for the following reason(s): (tick all that apply)

☒ (possible) lack of efficacy in adults

☒ (possible) lack of efficacy in children

☐ (possible) unsatisfactory safety profile in adults

☐ (possible) unsatisfactory safety profile in children

☐ commercial reasons (please specify:)

☐ manufacturing / quality problems

☐ other regulatory action (please specify:) (e.g. suspension, revocation of M.A.)

☐ other reason (please specify:)

Please add a brief description (max 2000 characters) of the reason(s) for the discontinuation / suspension:

The use of etrolizumab in the treatment of adult moderate to severe ulcerative colitis (UC) and crohn's diease (CD) has been investigated in six phase III studies and two additional phase III open-label extension studies.

In the Phase III studies for UC, Study GA29850 was designed to evaluate the efficacy and safety of etrolizumab during the induction and maintenance phases in patients who are refractory to or intolerant to TNF inhibitors. Study GA29102 was designed to evaluate the efficacy (maintenance of remission) and safety in patients naive to anti-TNF therapies. Two of the UC studies, Study GA28948 and Study GA28949, compared the efficacy of etrolizumab to placebo and adalimumab during the induction phase, while Study GA29103 was a head-to-head comparison of etrolizumab to infliximab in UC for both induction and maintenance phases in patients naive to anti-TNF therapies. The Phase III GA29144 in CD was evaluate the efficacy and safety of etrolizumab as an induction and maintenance treatment for patients with moderately to severely active CD.

However, mixed results were observed amongst the 6 pivotal studies and these results did not support a Marketing Authorisation application in adult patients for the treatment of UC or CD. As there was no evidence of a significant clinical benefit for the use of etrolizumab in adult UC and CD patients, the sponsor requests to discontinue development of etrolizumab in paediatric UC and CD patients.

Please note that if the PIP has been submitted as part of a marketing authorisation application in order to comply with the requirements of Article 7 of the Paediatric Regulation (as a condition of the validation of the respective application) and a marketing authorisation was granted based on this application, then there is a legal obligation to complete that PIP. The same applies if there has been a successful post-authorisation application, where the PIP was included in order to comply with the requirements of Article 8 of the Paediatric Regulation.

Please confirm if any of the above applies to the PIP in question:

Yes ☐ No ☒

If yes, it means that based on the Marketing Authorisation obtained at the end of that initial procedure or the successful post-authorisation application, as applicable, you are obliged to complete that PIP. That obligation cannot be cancelled by a unilateral decision, including by withdrawing the MA. Such PIP must be completed, unless it is modified in agreement with the PDCO by removing all outstanding PIP measures or granting a full product-specific waiver instead (upon relevant circumstances in accordance with the Paediatric Regulation). Non-completion of a binding PIP establishes noncompliance with the requirements of the Paediatric Regulation, which the European Medicines Agency has an obligation to report to the European Commission.

Name and signature of the PIP contact point:	Signature on file
Date:	22 March 2024

Contact for inquiries from interested parties:	Roche Registration GmbH
Telephone:	+41 616879411
Email:	info.paediatrics@roche.com